SCHEMBL555823

SCHEMBL555823

Cc1c(C(=O)O)ccc(N)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
KMT2A Q03164 4/20 0.48
TDP1 Q9NUW8 3/20 0.48
MEN1 O00255 2/20 0.48
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRB1 P18505 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA5 P31644 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
GABRA4 P48169 1/20 0.47
GABRE P78334 1/20 0.47
GABRA6 Q16445 1/20 0.47
GABRG1 Q8N1C3 1/20 0.47
GABRG3 Q99928 1/20 0.47
GABRQ Q9UN88 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27932861 0.98 KMT2A (0.48) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL2921220 0.86 GABRP (0.50) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL31494238 0.86 GABRP (0.50) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL30340194 0.84 KDM4E (0.50) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL93998 0.84 KDM4E (0.50) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL2926609 0.83 KDM4E (0.48) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL30374425 0.83 KDM4E (0.48) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL10661542 0.83 PARP1 (0.41) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL1457096 0.83 KDM4E (0.48) KDM4EKMT2ATDP1MEN1GABRP
SCHEMBL2880282 0.81 CASP7 (0.53) KDM4EKMT2ATDP1MEN1GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3818169-B1 METHOD FOR DETECTING SYNOVIAL JOINT INFECTIONS QUALIZYME DIAGNOSTICS GMBH & CO KG (AT) 2022-06-15 EP claimed
EP-3818169-A1 METHOD FOR DETECTING SYNOVIAL JOINT INFECTIONS Qualizyme Diagnostics GmbH & Co KG (AT) 2021-05-12 EP claimed
WO-2020008039-A1 METHOD FOR DETECTING SYNOVIAL JOINT INFECTIONS QUALIZYME DIAGNOSTICS GMBH & CO KG (AT) 2020-01-09 WO claimed
US-6805718-B2 USING AROMATIC AMINE, NAPHTHOL OR AMINONAPHTHALENE AND ENZYME NOVOZYMES A/S (DK) 2004-10-19 US claimed
US-6296672-B1 PEROXIDASE, OXIDOREDUCTASE, LACCASE NOVOZYMES A/S PATENTS (DK) 2001-10-02 US claimed
US-20260125348-A1 ARYL HYDROCARBON RECEPTOR ACTIVATORS OREGON STATE UNIVERSITY (US) 2026-05-07 US disclosed
EP-4710922-A2 ARYL HYDROCARBON RECEPTOR ACTIVATORS Oregon State University (US) 2026-03-18 EP disclosed
EP-4003337-B1 ARYL HYDROCARBON RECEPTOR ACTIVATORS UNIV OREGON STATE (US) 2026-03-11 EP disclosed
US-12473262-B2 Aryl hydrocarbon receptor activators OREGON STATE UNIVERSITY (US) 2025-11-18 US disclosed
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke UNIV EMORY (US) 2025-11-06 US disclosed
EP-3787631-B1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS UNIV EMORY (US) 2025-09-10 EP disclosed
US-12318393-B2 Modulators of orphan nuclear receptors for NASH and other metabolic disorders EMORY UNIVERSITY 2025-06-03 US disclosed
EP-0664792-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-09-25 EP disclosed
US-5559127-A ANTICOAGULANTS MERCK & CO., INC. (US) 1996-09-24 US disclosed
EP-0703819-A1 METHOD OF MAKING COMPOSITE GAS SEPARATION MEMBRANES UOP (US) 1996-04-03 EP disclosed
EP-0672031-A1 CATECHOL DIETHERS AS SELECTIVE PDE IV? INHIBITORS PFIZER INC. (US) 1995-09-20 EP disclosed
EP-0664792-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1995-08-02 EP disclosed
WO-1994029002-A1 COMPOSITE GAS SEPARATION MEMBRANES AND MAKING THEREOF UOP (US) 1994-12-22 WO disclosed
WO-1994012461-A1 CATECHOL DIETHERS AS SELECTIVE PDEIV INHIBITORS PFIZER INC. (US) 1994-06-09 WO disclosed
WO-1994008962-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12318393-B2 Modulators of orphan nuclear receptors for NASH and other metabolic disorders RORA, RORB, RORC KDM4E 3555/4885KMT2A 1778/4885TDP1 4386/4885
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke RXRA, RXRG, RXRB KDM4E 4329/4885KMT2A 3736/4885TDP1 3094/4885
US-20260125348-A1 ARYL HYDROCARBON RECEPTOR ACTIVATORS AHR, ARNT, NR1H2 KDM4E 2619/4885KMT2A 2141/4885TDP1 4328/4885
US-12473262-B2 Aryl hydrocarbon receptor activators AHR, ARNT, NR0B1 KDM4E 2779/4885KMT2A 1892/4885TDP1 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.